Novel coronavirus PCR testing, based on real-time reverse transcription polymerase chain reaction (RT-qPCR), is the internationally recognized reference method for detecting SARS-CoV-2 RNA in clinical specimens. This technical article explains the complete novel coronavirus PCR testing process, covering sample collection, nucleic acid extraction, amplification, quality control, and result interpretation, providing laboratories and healthcare organizations with a clear understanding of every stage of the molecular diagnostic workflow.
Technical Overview
Real-time reverse transcription polymerase chain reaction (RT-qPCR) is the gold-standard molecular technique for the qualitative detection of novel coronavirus (SARS-CoV-2) nucleic acid. The method works by converting viral RNA extracted from a respiratory specimen into complementary DNA (cDNA) through reverse transcription, and then exponentially amplifying targeted regions of the viral genome while monitoring fluorescence signal accumulation in real time.
Commercially available and laboratory-developed assays typically employ a dual-target or multi-target design, most commonly targeting the nucleocapsid (N) gene and the open reading frame 1ab (ORF1ab) region, with some kits additionally targeting the envelope (E), spike (S), or RNA-dependent RNA polymerase (RdRp) genes. Multi-target strategies reduce the risk of false-negative results caused by viral mutations in a single genomic region.
The entire testing process is divided into three phases: pre-analytical (sample collection, transport, and reception), analytical (extraction, amplification, and detection), and post-analytical (result interpretation, validation, and reporting). Laboratories performing SARS-CoV-2 PCR testing should operate under a quality management system conforming to ISO 15189 or ISO/IEC 17025 requirements, with physical containment and operational procedures appropriate for a biosafety level 2 (BSL-2) laboratory, and may hold accreditation from accredited third-party laboratories or national health authorities.
Testing Samples
Specimen type and collection quality are the most significant determinants of analytical sensitivity. Upper respiratory tract specimens are standard for routine diagnosis, while lower respiratory tract specimens may provide higher viral loads in patients with pneumonia.
Nasopharyngeal and Oropharyngeal Swabs
Nasopharyngeal swabs are generally considered the most sensitive upper respiratory specimen because the nasopharynx is a primary site of viral replication. Collection should be performed by trained personnel wearing appropriate personal protective equipment, using sterile synthetic fiber swabs (flocked nylon or polyester) with plastic or aluminum shafts. The swab is inserted through the nostril parallel to the palate, held for several seconds to absorb secretions, then placed immediately into a tube containing 2 to 3 mL of viral transport medium (VTM) or universal transport medium. Oropharyngeal swabs, which sample the posterior pharyngeal wall and tonsillar pillars, are often collected as a paired specimen combined into the same transport tube.
Saliva and Sputum
Deep-cough sputum may be collected from patients with productive cough, as lower respiratory secretions often carry a higher viral load. Self-collected saliva or saliva-oropharyngeal fluid has also been validated by many laboratories as an acceptable alternative, offering advantages for large-scale screening because it reduces exposure risk to sampling personnel and minimizes swab supply consumption.
Lower Respiratory Tract Specimens
In hospitalized patients with severe pneumonia, bronchoalveolar lavage fluid (BALF) or tracheal aspirates can be collected under clinical supervision. These specimens frequently contain higher viral concentrations but require invasive procedures and carry an elevated aerosol-generation risk, mandating enhanced biosafety precautions during collection and processing.
Other Specimen and Environmental Samples
Additional specimen types may include stool or anal swabs for gastrointestinal shedding studies, blood for research purposes, and environmental surface swabs from cold-chain food packaging, cargo, or high-touch surfaces. Environmental and cold-chain samples are typically tested in accredited third-party laboratories as part of source-tracing and contamination surveillance programs.
Specimen Transport and Storage
All specimens must be labeled with unique identifiers and accompanied by a test requisition form. Samples are transported as UN3373 Category B biological substances in leak-proof secondary containers. Recommended transport and short-term storage conditions are 2 to 8 degrees Celsius with testing completed within 24 to 72 hours of collection. For longer storage or delayed testing, specimens should be frozen at minus 70 degrees Celsius or below, avoiding repeated freeze-thaw cycles that degrade viral RNA.
Testing Items
The core testing item is the qualitative detection of SARS-CoV-2 RNA. A complete PCR assay panel typically includes the following components:
- SARS-CoV-2 RNA qualitative detection (positive, negative, or inconclusive result)
- Dual-target amplification of the ORF1ab gene and N gene, the most widely adopted target combination
- Supplementary targets such as the E gene, S gene, or RdRp gene used in confirmatory or screening algorithms
- Internal amplification control, typically the human RNase P gene, to verify specimen adequacy and extraction integrity
- Cycle threshold (Ct) values reported for each amplified target
- Optional multiplex respiratory panels for simultaneous detection of influenza A, influenza B, respiratory syncytial virus, and other pathogens presenting with similar clinical symptoms
Testing Methods
The analytical workflow is performed in physically separated areas to prevent amplicon contamination: a reagent preparation area, a sample processing area, and an amplification and analysis area, with unidirectional workflow between zones.
Phase 1: Specimen Reception and Inactivation
Upon arrival, specimens are inspected for leakage, verified against the requisition, and logged into the laboratory information system. Many protocols include a heat inactivation step, such as 56 degrees Celsius for 30 minutes, or chemical lysis in guanidinium-based buffers, which inactivates infectious virus while preserving RNA integrity for downstream analysis.
Phase 2: Nucleic Acid Extraction
Viral RNA is extracted from 200 to 400 microliters of the transport medium using either silica membrane column kits or magnetic bead-based extraction platforms, with automated extractors preferred for high-throughput testing. Extraction reagents incorporate carrier RNA to enhance recovery of low-copy viral genomes. An extraction negative control and an extraction positive control are processed alongside each batch to monitor cross-contamination and extraction efficiency. Extracted RNA is either amplified immediately or stored at minus 70 degrees Celsius.
Phase 3: RT-qPCR Amplification
Reaction mixtures are prepared in a clean area by combining the PCR master mix, which contains reverse transcriptase, heat-stable DNA polymerase, dNTPs, magnesium ions, and buffer, with virus-specific primers and dual-labeled fluorescent hydrolysis (TaqMan) probes. After template RNA is added, plates or tubes are sealed and transferred to the real-time PCR instrument. A typical cycling program consists of reverse transcription at approximately 50 degrees Celsius for 10 to 30 minutes, initial denaturation and polymerase activation at 95 degrees Celsius, followed by 40 amplification cycles of denaturation around 94 to 95 degrees Celsius and annealing and extension at 55 to 60 degrees Celsius with fluorescence acquisition at each cycle.
Phase 4: Quality Control and Result Interpretation
Each run must include a no-template negative control, a positive control with known viral RNA, and the internal control channel for each specimen. The run is valid only if all controls perform within predefined specifications. Results are interpreted according to the kit insert, generally as follows:
- Positive: both target channels show exponential amplification with Ct values below the validated cutoff, commonly 35 to 40 depending on the assay
- Negative: no amplification in either target channel while the internal control amplifies within the expected Ct range, confirming specimen adequacy
- Inconclusive or single-target reactive: one target amplifies while the other does not, requiring repeat extraction and testing, or re-sampling if the pattern persists
- Invalid: failure of the internal control in the absence of target amplification, indicating possible extraction failure or inhibition, requiring retesting
Ct values are inversely related to viral RNA quantity; low Ct values indicate high viral load, while Ct values approaching the cutoff indicate low viral RNA concentrations near the detection limit. Borderline results should always be interpreted alongside clinical presentation and epidemiological history.
Phase 5: Validation and Reporting
Qualified personnel review control data, amplification curves, and specimen records before authorizing results. Reports clearly state the assay targets, methodology, result, and interpretive comments. Critical results, particularly positives in screening contexts, are communicated promptly to requesting clinicians and public health authorities in accordance with national reporting requirements, while maintaining patient confidentiality.
Applications
Novel coronavirus PCR testing supports a wide range of clinical and public health use cases:
- Clinical diagnosis of suspected COVID-19 cases and confirmation in symptomatic patients
- Screening of close contacts and outbreak investigation in communities and congregate settings
- Entry screening at ports, airports, and border crossings, including pre-departure and on-arrival testing programs
- Pre-operative, pre-admission, and pre-procedural screening in hospitals to protect vulnerable patients and staff
- Regular surveillance testing in workplaces, schools, universities, long-term care facilities, and mass gathering events
- Cold-chain food, packaging, and cargo testing for contamination monitoring and source tracing
- Environmental surface and wastewater surveillance to estimate community viral circulation trends
- Endpoint monitoring in vaccine clinical trials and antiviral therapeutic studies
FAQ
How long does the novel coronavirus PCR testing process take?
The hands-on laboratory process, from extraction through amplification and result review, typically takes 4 to 6 hours. Including logistics, batch scheduling, and reporting, most laboratories deliver results within 12 to 24 hours of specimen receipt. Rapid PCR platforms can shorten analytical time to under one hour for point-of-care settings.
What does the Ct value mean?
The cycle threshold (Ct) is the number of PCR cycles required for the fluorescent signal to exceed the background level. It is inversely proportional to the amount of viral RNA in the specimen: a Ct of 20 suggests a high viral load, while a Ct near 35 to 40 indicates a very low viral RNA concentration close to the assay detection limit. Ct values are semi-quantitative and should not be used as precise viral load measurements.
Why can a PCR test be negative in a person who is actually infected?
False negatives mainly arise from improper swab collection technique, testing too early or too late in the infection course when viral load in the sampled region is below detection, specimen transport or storage degradation, or rare primer-probe mismatches caused by viral mutation. When clinical suspicion remains high, repeat testing with a fresh specimen, ideally a nasopharyngeal swab or lower respiratory sample, is recommended.
How does PCR testing differ from antigen testing?
PCR detects viral genetic material through nucleic acid amplification, offering very high analytical sensitivity and the ability to detect low-level infections. Rapid antigen tests detect viral proteins using immunochromatography and are faster and cheaper but less sensitive, particularly in asymptomatic or low viral load individuals. PCR is generally used to confirm antigen-positive results or to resolve discordant cases.
Can PCR testing detect a past infection?
No. PCR detects current viral RNA and cannot determine prior exposure or immunity history. Serological antibody tests, which measure the immune response rather than the virus itself, are used for retrospective epidemiological investigation of past infection.
What biosafety precautions are required during testing?
Laboratories process specimens under biosafety level 2 conditions with additional operational precautions, including biological safety cabinets for open-tube manipulations, validated inactivation procedures before extraction, full personal protective equipment for staff, unidirectional workflow to control amplicon contamination, and certified biosafety cabinets and autoclaves for waste decontamination.